Teduglutide

GLP-2 Analog — ALIMENTARY TRACT AND METABOLISM

Key facts

Teduglutide is a drug in the GLP-2 Analog class catalogued in DrugCentral. It was first approved by the EMA in 2012. Its mechanism of action is classified as Glucagon-like Peptide-2 (GLP-2) Agonists. DrugCentral lists 2 molecular targets, including Glp2r and GLP2R. Recorded indications include Short bowel syndrome.

• Drug class: GLP-2 Analog.
• Mechanism of action: Glucagon-like Peptide-2 (GLP-2) Agonists.
• Molecular targets: Glp2r and GLP2R (2 listed in DrugCentral).
• Indications: Short bowel syndrome.
• ATC code: A16AX08 (Various alimentary tract and metabolism products).
• Molecular formula: C164H252N44O55S; molecular weight 3752.14 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Short bowel syndrome

Mechanism & targets

• Mechanism of action (MoA): Glucagon-like Peptide-2 (GLP-2) Agonists
• Established pharmacologic class: GLP-2 Analog

Molecular targets (2)

Target	Gene	Action	Activity
Glucagon-like peptide 2 receptor	Glp2r	unknown	EC50 10.10
Glucagon-like peptide 2 receptor	GLP2R	agonist	EC50 10.05

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	TAKEDA PHARMACEUTICAL COMPANY LIMITED	Yes
2012-12-21	FDA	—	NPS PHARMS INC	Yes
2012-08-30	EMA	—	NPS Pharma Holdings Limited	Yes

ATC classification

ATC code	Therapeutic hierarchy
A16AX08	ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Vascular device infection	3030.5
Stoma complication	775.4
Device related infection	762.7
Device related sepsis	590.3
Gastrointestinal stoma output increased	531.7
Product dose omission issue	356.1
Abdominal distension	351.7
Weight decreased	351.3
Dehydration	330.9
Abdominal pain	294.8
Intestinal obstruction	253.5
Gastrointestinal stoma complication	239.8

Chemical structure

• Molecular formula: C₁₆₄H₂₅₂N₄₄O₅₅S
• Molecular weight: 3752.14 g/mol
• CAS number: —
• InChIKey: CILIXQOJUNDIDU-ASQIGDHWSA-N
• PubChem CID: 16139605

CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Teduglutide used for?

DrugCentral lists the following indications for Teduglutide: Short bowel syndrome.

How does Teduglutide work?

Teduglutide is classified as Glucagon-like Peptide-2 (GLP-2) Agonists; its molecular targets in DrugCentral include Glp2r and GLP2R (agonist).

When was Teduglutide first approved?

Teduglutide was first approved by the EMA in 2012.

What drug class does Teduglutide belong to?

Teduglutide is in the GLP-2 Analog class.

What is the chemical formula of Teduglutide?

Teduglutide has the molecular formula C164H252N44O55S and a molecular weight of 3752.14 g/mol.

Sources

• DrugCentral drug card 4718 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2104987 — compound record and bioactivity
• PubChem CID 16139605 — chemical identifiers
• DrugBank DB08900 — drug record
• FDA UNII 7M19191IKG — substance identity
• DailyMed: FDA labels for Teduglutide — current prescribing information (label search)
• UniProt O95838 (GLP2R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.